Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.35 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.30 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24312556 | 0.90 | RIPK1 (0.34) | POLRMTTMPRSS2RIPK1DOT1L | |
| SCHEMBL24917062 | 0.90 | POLRMT (0.34) | POLRMTTMPRSS2RIPK1DOT1L | |
| SCHEMBL25607768 | 0.89 | POLRMT (0.34) | POLRMTTMPRSS2RIPK1DOT1L | |
| SCHEMBL24917146 | 0.89 | TSHR (0.35) | POLRMTPIK3CD | |
| SCHEMBL26944457 | 0.89 | POLRMT (0.33) | POLRMTTMPRSS2RIPK1 | |
| SCHEMBL26213459 | 0.89 | POLRMT (0.33) | POLRMTTMPRSS2RIPK1 | |
| SCHEMBL24312545 | 0.89 | POLRMT (0.33) | POLRMTTMPRSS2RIPK1DOT1L | |
| SCHEMBL26944556 | 0.89 | POLRMT (0.33) | POLRMTTMPRSS2RIPK1DOT1L | |
| SCHEMBL24312614 | 0.88 | RIPK1 (0.33) | POLRMTTMPRSS2RIPK1SLC5A1SLC5A2 | |
| SCHEMBL24312579 | 0.88 | RIPK1 (0.33) | POLRMTTMPRSS2RIPK1SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054618-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | POLRMT 138/4885TMPRSS2 100/4885PIK3CD 3488/4885 |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | POLRMT 20/4885TMPRSS2 141/4885PIK3CD 4640/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | POLRMT 20/4885TMPRSS2 141/4885PIK3CD 4640/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | POLRMT 20/4885TMPRSS2 141/4885PIK3CD 4640/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | POLRMT 138/4885TMPRSS2 100/4885PIK3CD 3488/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | POLRMT 138/4885TMPRSS2 100/4885PIK3CD 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.